he circadian clock sustains self-perpetuating oscillations with a 24-h periodicity and is simultaneously synchronized with external environmental cues such as light, temperature and food intake, the so-called 'zeitgebers' , or time-givers, that maintain an organism's proper timekeeping (Fig. 1) . Disruptions in biological rhythms result in numerous physiological disorders in organismal homeostasis, with consequences that have been linked to several pathologies, including cancer 1, 2 . Specifically, epidemiological and laboratory evidence has long suggested that a relationship exists between the circadian clock and cancer
, which is supported by preclinical data. However, the precise mechanisms underlying the relationship between clock disruption and cancer initiation and/or progression remain unknown. This Perspective will summarize the current state of knowledge regarding the links between the circadian clock ( Fig. 2 and Box 1) and cancer in an effort to highlight new avenues for therapeutic intervention. Specifically, we discuss recent advances in teasing out how the clock is implicated in regulating cancer-initiating cells as well as utilization of genetic mouse models of cancer in which circadian disruption alters disease progression. Additionally, we focus on several facets of cancer metabolism that can be rewired in response to circadian disruption. We intend to highlight new directions in need of further research emphasis to fully understand how clock disruption and cancer converge in addition to new avenues of pharmacological intervention for treatment of cancer.
Links between circadian disruption and cancer
Epidemiological links between the clock and cancer. Circadian disruption has been associated with increased incidence of specific cancers in various epidemiological studies, though the causes and factors linked with this disruption remain somewhat unclear. In 2007, the International Agency for Research on Cancer (IARC) listed "shift work leading to a disruption in circadian rhythm" as a probable human carcinogen, classified as Group 2A 7 . The most convincing epidemiological evidence relates to studies on shift workers and, more recently, to meal timing. Accumulating data show a correlation between shift work and breast and prostate cancer [4] [5] [6] . For example, according to the Nurses' Health Study and case-controlled studies conducted with Norwegian nurses, women that worked night shifts for less than 30 years had a moderately increased risk for breast cancer, and risk was further increased upon working 30 or more years of rotating shift work (relative risk (RR) = 1.36) 4, 6, 8 . Similarly, reports suggest that the risk of prostate cancer is increased in night-shift workers, and this risk is augmented with a longer duration of shift work, particularly for highgrade cancers 5, 9 . Moreover, exposure to light at night may not be the only risk factor influencing circadian disruption and tumorigenesis. A prospective study of 41,398 day-working adults in the French NutriNet-Sante cohort identified that 'late-eaters' (those that exhibited eating episodes after 9:30 p.m.) have an increased risk of breast and prostate cancer, with hazard ratios (HR) of 1.48 and 2.20, respectively 10 . With these epidemiological studies as a basis, we further discuss the effect of environmental disruption of the clock on cancer below.
Linking the circadian clock and cancer in animal models.
Although limited, the epidemiological evidence summarized above broadly linking circadian disruption with cancer has triggered a significant number of studies using genetic mouse models (Fig. 3) . Although drawing parallels between epidemiological information and results from mouse experimental models is always difficult, significant evidence for a link between circadian clock disruption and increased cancer risk has accumulated. Early landmark studies have shown that mice carrying mutations in individual genes related to the circadian clock (mutation of period 2 (Per2 m/m ); heterozygous ablation of aryl hydrocarbon receptor nuclear translocatorlike protein 1 (Arntl) (Bmal1 +/-); and double-null cryptochrome 1 (Cry1) and Cry2 (Cry1/2 -/-)) are more susceptible to lymphoma, and when irradiated, these mutant mice have increased rates of lymphoma and hepatocellular carcinoma 11, 12 . Recent evidence demonstrates that crossing Per2 m/m mice with a Kras LSL-G12D/+ ;p53 fl/fl genetically engineered mouse model (GEMM) of lung adenocarcinoma resulted in increased tumor burden, more aggressive grade 3 and 4 lung tumors, and subsequent decreased overall survival 13 . Altogether these studies provide compelling support for the notion that genetic disruption of key components of the clock mechanism
The emerging link between cancer, metabolism, and circadian rhythms increases tumorigenesis, but it is still unclear whether there is any specificity for distinct types of cancer.
Notably, animal studies indicate that tumorigenesis may be linked to anatomical disruption of the central circadian pacemaker housed in the suprachiasmatic nucleus (SCN), though the effects on peripheral clocks remains unresolved. Bilateral electrolytic lesions of the SCN enhanced tumor growth of implanted Glasgow osteosarcoma and pancreatic ductal adenocarcinoma (PDAC) versus sham-operated mice 14 . Yet, the molecular mechanisms by which disruption of the central pacemaker results in enhanced tumorigenesis is unknown and likely involves changes in the synchrony between the SCN and peripheral clocks.
Environmental disruption of the circadian clock and cancer.
Epidemiological studies indicate that disruption of circadian rhythms in humans is associated to increased cancer risk (see above). In addition, pilot data now suggest that shift work can also regulate the epigenetic landscape, which could likely be a mechanism by which circadian gene expression is altered [15] [16] [17] . For instance, in female shift workers from a prospective cohort in Denmark, DNA methylation studies have found genome-wide alterations to cancer-specific and circadian loci, including estrogen receptor α (ESR1) and the circadian genes clock (CLOCK) and cryptochrome 2 (CRY2) 17 . On a genome-wide scale, 5,409 CpG sites were found to be differentially methylated in day-time versus night-time shift workers, and a remarkable 66% of these loci were hypermethylated 17 . Similarly, CpG methylation of the PER1, PER2 and PER3 promoters was found to correlate with changes in protein expression in 50% of breast tumors versus normal tissue taken from the same patient 15 . Moreover, in 126 cases of several types of hematologic malignancies, Bmal1 gene silencing due to CpG promoter methylation was found in 19.7% of diffuse large B cell lymphomas, 33.3% of acute lymphocytic leukemias, and 19.2% of acute myeloid leukemias 16 . These findings are intriguing and suggest an active mechanism by which epigenetic modifications may alter genome-wide gene expression programs under shift-work conditions. Yet, several questions remain. Are these shift-work-induced changes to the epigenome a direct result of nighttime light exposure? How does this work mechanistically? How quickly do these events occur, and are they reversible? These questions remain fully unresolved, but addressing them would shed light on the active epigenetic mechanism or mechanisms that are environmentally controlled by day-night rhythms to impinge on tumorigenesis.
Importantly, environmental disruption of the central-peripheral circadian axis by chronic jet lag has been modeled in animals. For instance, wild-type (WT) mice undergoing repeated jet lag manipulation display disrupted gene expression of the circadian repressors Per2 and nuclear receptor subfamily 1 group D member 1 (Nr1d1, also known as Rev-Erbα), resulting in increased growth of Glasgow osteosarcoma 18 as well as enhanced incidence of lymphoma and hepatocellular carcinoma (HCC) 12 . Although it is unclear why circadian disruption impacts specific tumors, similar experiments have been performed with a variety of mice with mutations in clock genes,
. These mutant mice display a heightened incidence of lymphoma, osteosarcoma and HCC relative to WT mice when subjected to severe chronic jet lag 12 . Recent laboratory data have shed light on the molecular mechanisms of circadian disruption through jet lag and its link with tumorigenesis. Long-term jet lag initiates a program of nonalcoholic fatty liver disease (NAFLD) that progresses to steatohepatitis, fibrosis, and eventually HCC in mice 19 . Jet lag operates by disrupting both circadian gene expression programs as well as circadian metabolism in the liver, and central to this rewiring is an induction of hepatic cholesterol and bile acid levels, which activate the oncogenic program of the nuclear receptor constitutive androstane receptor (CAR), and downstream activation of β -catenin 19 .
Collectively these findings implicate a critical signaling axis that coordinates the central pacemaker with peripheral circadian transcription and metabolism, though the implications of these findings in humans remains unresolved (Box 2).
Circadian control of cancer metabolism
Crosstalk between Myc and the circadian clock. Given that the clock is intimately involved in regulating metabolism in peripheral tissues 20, 21 and the majority of metabolites in liver and serum are controlled in a cyclic manner [22] [23] [24] , the intersection of cancer metabolism and its control by the circadian clock is an area of active investigation. A study reported the role of the MYC (c-Myc) oncogene in regulating rhythmic metabolism in cultured U2OS human osteosarcoma cells 25 . The MYC protein has oncogenic potential due to its capacity to activate gene expression programs related to survival and proliferation [26] [27] [28] . In an inducible system, ectopic expression of MYC was found to disrupt the expression of circadian genes. MYC was found to activate the negative transcriptional arm of the clock through REV-ERBα ( Fig. 2 and Box 1) and to stimulate metabolic sensing pathways such as AMP-activated protein kinase (AMPK; a kinase whose enzymatic activity depends on cellular metabolic state), ultimately leading to increased consumption of glucose and glutamine 25 . This specific case illustrates another scenario where an oncoprotein disrupts circadian function with subsequent effects on cellular metabolism. It is tempting to speculate that altered metabolism could provide feedback to cellular growth and clock function, contributing to the unbalanced state characteristic of tumor cells.
These findings in cells cultured in vitro have been further validated in vivo via genetically engineered mice. One study took advantage of the Kras LSL-G12D/+ ;p53
fl/fl mouse model. These mutant mice are prone to cancer because they carry an activated Kras oncogene and an inactivation of the tumor suppressor p53 13, 29 . The authors genetically ablated either the clock gene Per2 or Bmal1 in mice and crossed them with the Kras LSL-G12D/+ ;p53 fl/fl line. This ablated the circadian clock and resulted in elevated consumption of glucose and glutamine, which increased excretion of lactate as compared to the Kras LSL-G12D/+ ;p53 fl/fl mice with an intact clock 13 . These studies suggest that disruption of the clock caused by the ablation of the CLOCK, BMAL1, and MYC are all transcription factors that share a highly similar basic helix-loop-helix (bHLH) protein domain, allowing these proteins to recognize the same promoter element, the enhancer box (E-box) sequence 30, 31 , in the regulatory regions of target genes. It is thus tempting to speculate that a rewiring could take place during tumorigenesis, whereby the balance of clock-controlled transcription can be lost and consequently compensated for by oncogenic MYC signaling. In further support of this idea, the circadian repressor CRY2 has been reported to promote MYC degradation through the FBXL3-containing E3 ligase, and Cry2 deletion has resulted in enhanced MYC-driven lymphomas in mice 32 . Also, it has been shown that MYC and its binding partner MIZ1 are responsible for forming a repressive complex that downregulates core clock gene expression 33 . Further confirming these findings, the expression of BMAL1 was found to be inversely correlated with MYC in 102 human lymphoma samples 33 . These data suggest a counterbalance may exist between the transcriptional networks of the circadian clock and MYC. What remains to be fully elucidated is the functional significance of this potential transcriptional switch from canonical CLOCK-BMAL1 control to MYCdependent signaling, and therefore the extent of the prospective shared gene expression network in normal and transformed cells that regulates metabolism.
Although several studies described above have utilized human cells cultured in vitro or GEMMs, the clinical relevance of these studies is hard to assess. Yet, it could be speculated that alteration in human metabolism brought by, for example, nutritional challenges, could disrupt circadian homeostasis in ways that would parallel some mouse models of clock disruption. Indeed, the effects of nutritional challenge on circadian reprogramming and alterations in rhythmic homeostasis have been reported 23, 24, [34] [35] [36] [37] . Studies in mouse models as well as in human subjects have shown the remarkable effect of specific dietary regimes, such as a high-fat diet 23, 24, 38 , as well as that of time-restricted feeding 24, 34, [39] [40] [41] on the circadian clock. Also, metabolomics analyses in human serum, plasma, and skeletal muscle have identified major populations of rhythmic metabolites over the circadian cycle 42, 43 . Therefore, further investigation is required to determine the role of nutritional inputs on circadian metabolism and tumorigenesis.
The circadian clock and oxidative stress in cancer. Oxygen is critical for cellular respiration, and hypoxia has been shown to play a regulatory role in tumorigenesis linked to metabolism and angiogenesis 26, 27 . Moreover, a transcriptional crosstalk exists between the clock and the transcription factor hypoxia-inducible factor (HIF), a potential scenario that may be extended to tumorigenesis. The promoter element recognized by HIF, the hypoxia-response element (HRE), is an E-Box-like sequence that contributes to transcription under low-oxygen conditions. The HRE is recognized by HIF heterodimers consisting of two highly similar proteins, HIF1α and HIF1β . Recent reports indicate that the hypoxic response is gated by the circadian clock as the HIF1α promoter is directly controlled by CLOCK-BMAL1 (ref. 44 ). Similarly, blood oxygen levels were found to exhibit daily rhythms that influence expression of core clock genes in a HIF1α -dependent manner in kidney, brain, and hepatocytes 45 . This transcriptional crosstalk was further supported by the fact that genetic disruption of Bmal1 in C2C12 myotubes results in reduced anaerobic glycolysis, the gene targets of which are HIF1α -dependent 46 . These studies establish an intriguing link between the transcriptional networks of the clock system with HIF1α and potentially suggest that this crosstalk could be involved in the hypoxic response during tumorigenesis. In addition, it remains to be determined whether glycolytic metabolism of cancer cells could depend on a HIF1α axis that interplays with the clock machinery.
Interestingly, several lines of epidemiological evidence connecting circadian disruption due to shift work with cancer have largely focused on hormone-dependent diseases such as breast and prostate cancer, which raises the possibility that additional clock-controlled endocrine factors may be at play. One such link has been made with melatonin, a hormone produced by the pineal gland in a circadian manner to regulate sleep 47, 48 . Melatonin has been linked to regulation of oxidative stress mostly in the mitochondria 49 , where melatonin is reported to stimulate the activity of glutathione peroxidase (GPx) and glutathione reductase (GRd), two enzymes involved in regulation of the glutathione:glutathione disulfide ratio 50, 51 . Interestingly, melatonin regulates the mitochondrial respiratory complexes I and IV and thereby modulates ATP production 50, 52 . Therefore, melatonin may antagonize the glycolytic dependency of cancer cell metabolism in a time-dependent manner by targeting mitochondrial function 53 . Notably, dampened melatonin secretion caused by sleep disruption may increase reactive oxygen species (ROS) levels and reactive nitrogen species (RNS) production, as suggested by studies in night-shift workers 54 .
Tumor macroenvironment and circadian metabolism
The tumor environment can be extended beyond the microenvironment to a systems-level approach examining tumor-host interactions that are especially relevant to the circadian metabolic clock (Fig. 4) . The tumor 'macroenvironment' consists of metabolites and other tumor-secreted factors (such as cytokines and chemokines) that circulate in the blood 55 . Accumulating evidence illustrates the significant role that the tumor macroenvironment may play in connecting systemic metabolism and cell proliferation 56, 57 . In this respect, specific components of the circadian clock machinery may be highly susceptible to factors secreted by the tumor, given that the clock is especially vulnerable to metabolic fluctuations such as those caused by different types of nutritional regimes 23, 24, 34, 37 . In the . CLOCK-BMAL1-dependent transcription of core clock and clock-controlled genes (CCGs) peaks during the day, while transcription is inhibited by the circadian repressors period (PER) and cryptochrome (CRY) at night [104] [105] [106] . An additional level of circadian regulation exists with the nuclear receptors RORα and REV-ERBα , which activate and repress transcription of the BMAL1 gene, respectively 107, 108 . fl/fl mouse model, lung adenocarcinoma was found to distally rewire the circadian transcriptome and metabolome in the liver 58 . This finding illustrates a communication system from the lung to the liver mediated by the tumor macroenvironment, as revealed by changes in the metabolite composition in the serum. Tumor-dependent inflammation through the IL-6 pathway dampened insulin and glucose sensitivity and altered hepatic circadian lipid metabolism 58 . Similarly, in a mouse model of triple-negative breast cancer, rewiring of circadian gene expression was distally observed in the liver, resulting in increased oxidative stress 59 . These findings raise the possibility that tumor-host interaction may influence cancer cell viability and specifically that circadian oscillations of metabolism may be highly susceptible to systemic cues that reorganize physiological homeostasis. To date, rewiring of circadian metabolism in response to tumorigenesis has been reported within the context of mouse models of lung and breast cancer, but other types of cancers that function similarly, as well as the extent of this rewiring in all peripheral tissues systemically, remain unknown.
Can the circadian clock feedback and regulate properties of tumorigenesis? If so, what are these circadian cues that modulate cancer progression systemically? Interestingly, BMAL2 has been reported to regulate lung adenocarcinoma distal metastasis through a unique tumor-dependent 'secretome. ' BMAL2 was found to be highly expressed in primary metastatic tumors in the Kras LSL-G12D/+ ;p53 fl/fl ;R26 LSL-Tom lung adenocarcinoma model, which utilizes a tomato reporter to track sites of metastases 60 . Also, BMAL2 was required for metastasis by regulating the expression of secreted modular calcium-binding protein 2 (Smoc2), which is critical for anchorage-independent growth and metastatic seeding in vivo 60 . BMAL2 expression has been associated with lung adenocarcinoma metastases in humans while being silenced within the tumor. Parallel experiments in cell culture and in mice have shown that BMAL2 contributes to the clonogenic ability of lung adenocarcinoma cells, and it directs the activation of genes encoding secreted factors. These in turn are involved in prometastatic function, revealing that the clock protein BMAL2 is involved in regulating a metastatic secretome consisting of Smoc2, Wnt5a, and Ccl7 (ref. 60 ). These findings suggest a crosstalk between the circadian clock and cancer cells through the tumor-derived macroenvironment and underscore the ability of canonical and noncanonical clock components to regulate a metastatic secretome. Further investigation is needed to better understand how the clock controls metastasis in different cancer types and how this tumor-dependent secretome may differ because of disease profile.
Importantly, evidence also suggests that tumor-derived waste can be repurposed and subsequently utilized as fuel for tumors. Clinical and laboratory studies have provided evidence that NSCLC exhibits metabolic heterogeneity in fuel utilization and, while
Box 1 | Mammalian circadian clocks
Physiological and metabolic variations follow cycles linked to the time of the day. These circadian (from the Latin words, circa diem, about a day) rhythms include sleep-wake cycles, feeding behavior, body temperature, and hormonal oscillations (Fig. 1) . All cells harbor molecular clocks that operate in concert to control circadian rhythms 98, 109 . The architecture of the circadian system is based on a hierarchical structure whereby the central oscillator receives environmental cues, known as zeitgebers, that can adjust the otherwise self-sustained rhythms driven by the clock 110, 111 . From an anatomical standpoint, the circadian system is based on a central clock located in the suprachiasmatic nucleus (SCN) within the hypothalamus 112, 113 . Neurons within the SCN function autonomously and are reset in response to light to coordinate the timekeeping of peripheral clocks located in all other tissues and cells in the body 111, 114, 115 . Therefore, proper synchronization and coordination between central and peripheral clocks is thought to be of upmost importance for systemic homeostasis.
The molecular organization of the core circadian clock has been unveiled over the past couple of decades (Fig. 2) . The molecular machinery that constitutes the circadian clock is comprised of two DNA-binding transcription factors, CLOCK and BMAL1, that heterodimerize and direct transcriptional activation of core clock genes and additional clock-controlled genes (CCGs) 104, 105 by binding to E-box sites on their promoters 30 . Among these CCGs, CLOCK and BMAL1 direct transcription of their own repressors, PER and CRY family members, creating a tightly self-regulated transcriptional-translational feedback loop 110, 113, 116 . During the day, transcription of PER and CRY is high, resulting in translation of the circadian repressors and subsequent formation of the inhibitory complex with CLOCK and BMAL1 that abolishes transcription of CCGs at night 106 . Degradation of the circadian repressors PER and CRY alleviates transcriptional repression and restores CLOCK-BMAL1-mediated transcription, establishing an oscillatory rhythm in circadian gene expression that operates within a precise 24-h period. An additional level of circadian regulation exists with the orphan nuclear receptors RORα and REV-ERBα , which activate and repress transcription of the BMAL1 gene, respectively 107, 108, 110, 113 .
Transcriptome studies have shown that the clock directs the expression of a large number of genes in different tissues, illustrating that a significant fraction of the genome is under clock control [102] [103] [104] . This notion implicates cyclic chromatin transitions to occur on a genome-wide scale, and a number of chromatin remodelers have been found to display circadian activity. For example, the core regulator CLOCK displays acetyltransferase activity on nonhistone proteins 117, 118 and on H3 at K9 and K14 (ref. 119 ), both marks associated to a chromatin state permissive for transcription. The CLOCK-BMAL1 heterodimer appears to interact also with CREB-binding protein (CBP), p300 and the CBP-associated factor PCAF 120, 121 , suggesting that a number of HATs may contribute to the circadian epigenome. Additionally, various histone deacetylases (HDACs) have been implicated, such as HDAC1 (ref. 106 ) and HDAC3 (ref. 122, 123 ), in addition to the nicotinamide adenine dinucleotide (NAD + )-dependent sirtuins, SIRT1 (ref. 73, 74, 124 ) and SIRT6 (ref. 75 ), which are regulated by cyclic availability of NAD + through the salvage pathway 77, 78 . In addition to acetylation, histone methylation has been also implicated in circadian chromatin remodeling through histone methyltransferases (myeloid/lymphoid or mixed-lineage leukemia 1) MLL1 (ref. 125 ) and MLL3 (ref. 126 ). Specific molecular components of the circadian clock machinery are listed below:
1. Circadian locomotor output cycles kaput (CLOCK), core transcription factor 2. Aryl hydrocarbon receptor nuclear translocator-like protein 1 (ARNTL or BMAL1), core transcription factor 3. Period 1-Period 3 (PER1-PER3), transcriptional repressors 4. Cryptochrome 1 and 2 (CRY1 and CRY2), transcriptional repressors 5. Nuclear receptor subfamily 1, group D, member 1 (REV-ERBα , also known as NR1D1), transcriptional repressor 6. Retinoid-related orphan receptor alpha (RORα ), transcriptional activator glucose oxidation is metabolically imperative, lactate can also be used as a carbon source [61] [62] [63] . A similar example exists with nitrogen repurposing of ammonia waste that was reported to be recycled into central amino acid metabolism through the enzymatic activity of glutamate dehydrogenase in breast cancer cells 64 . These studies suggest a mechanism by which the tumor-derived macroenvironment can be recycled as alternative fuel sources for rapidly proliferating cells. Given the fundamental role of the circadian clock in regulating metabolism, including pathways involved in carbohydrate, amino acid, and fatty acid and lipid metabolism 20, 65 , it is plausible that the circadian clock may be involved in regulating these processes in the context of cancer. Also, it is possible that tumordependent metabolic waste may be secreted in a temporal manner, suggesting peak times of day whereby these metabolic pathways could be targeted pharmacologically.
Clinical relevance of chronotherapy for cancer
The multiple connections discussed here between clock disruption and cancer beg the question of whether circadian therapeutic intervention (such as time of day) should be considered for treatment of cancer. This so-called 'chronotherapy' has been recently reviewed in depth 66 , and evidence strongly supports the idea that metabolic and xenobiotic detoxification enzymes exhibit temporal peaks in activity and thus should be pharmacologically targeted based on optimal time of day.
Several pathways relevant to the circadian clock are currently being targeted for cancer therapy, and we highlight several potential avenues whereby circadian intervention approaches (such as time of day) could be considered. For instance, inhibition of acetyl-CoA carboxylase (ACC) and subsequent decreased fatty acid synthesis in mouse models of lung adenocarcinoma effectively dampened tumor growth 67 . Similarly, acetyl-CoA synthetase (ACSS2) has been reported to supply tumors with acetate-dependent acetylCoA that is used for de novo lipogenesis and histone acetylation 68, 69 . These studies implicate pathways that have been previously reported to be clock-controlled. For example, the enzymatic activity of ACSS2 is modulated by NAD + -dependent sirtuin 1 (SIRT1) and a functional clock to control acetyl-CoA production and fatty acid synthesis 70 . Therefore, this raises the possibility that changes in clock-controlled ACSS2 activity can potentially influence tumorigenesis and suggest that an approach with a time-of-day intervention should be considered. Recent evidence also suggests that pharmacological agonists of REV-ERB are selectively lethal to cancer cells and impair growth of glioblastoma in vivo 71 . These findings require further examination to determine whether this type of approach would be effective in other cancer types.
Metformin has been reported to impair respiration by inhibiting mitochondrial complex I and altering the NAD + :NADH ratio 72 . This treatment strategy for cancer is especially appealing from a circadian perspective, given that the clock machinery is subject to NAD + -dependent control through the mammalian sirtuins [73] [74] [75] [76] . Also, the circadian clock is reported to regulate the cyclic availability of NAD + by controlling the rhythmic activity of nicotinamide phosphoribosyltransferase (NAMPT) 77, 78 , a critical enzyme in the NAD + -salvage pathway. Therefore, future pharmacological intervention may need to consider possible strategies to restore clock function, especially at late stages of cancer progression when a decline of circadian output is believed to occur. Indeed, rescue of carcinogen-dependent decline of the NAD + :NADH ratio in The tumor macroenvironment, comprised of inflammatory cytokines, chemokines, glycolytic byproducts, and other tumor-derived waste, is secreted into the blood. Emerging evidence now suggests that metabolic waste byproducts, such as lactate, can potentially be utilized as carbon sources to satisfy the demand of rapidly proliferating cells 61 . The ability of the circulating tumor macroenvironment to rewire circadian metabolism at a distance has been described 58, 59 . Target metabolic tissues include the liver but likely extend to the pancreas, adipose tissue, and skeletal muscle, as shown. In addition, the role of peripheral tissues in further driving tumorigenesis by potentially supplying metabolic fuel emphasizes the significance of tumor-host interaction. mammary epithelial cells restored SIRT1 activity and rhythmic expression of the circadian gene Per2 (ref. 79 ). Conversely, given the elevated metabolic demand of rapidly proliferating cells, an alternative treatment strategy involves suppression of NAD + levels to inhibit tumor growth. For instance, pharmacological suppression of NAMPT and the subsequent depletion of intracellular NAD + levels has been demonstrated to induce apoptosis in several leukemic cell lines and to abrogate tumor growth in mouse models of AML 80, 81 . This NAD + -starvation strategy requires further experimental validation, as it remains unclear what the resulting effect on circadian function will be. Yet, given that the clock is reported to be required for AML development 82 , suppression of NAD + levels in hematologic tumors may differ from solid tumors in treatment efficacy.
Additionally, the circadian hormone melatonin has been used in combination with cancer therapy to minimize toxicity or enhance chemotherapeutic viability in clinical and laboratory settings. For example, melatonin protects against cisplatin-induced ROS production and mitochondrial damage through glutathione in mouse ovaries to minimize reproductive toxicity 83 . Melatonin has also been used in combination with 5-fluorouracil (5-FU) to enhance the inhibitory effect on colon cancer cell proliferation by suppression of the PI3K-AKT survival pathway and NFκ B-dependent activation of the inducible nitric oxide synthase (iNOS) signaling pathway 84 . Lastly, melatonin has been reported to inhibit the epithelial to mesenchymal transition (EMT) by increasing E-cadherin expression and decreasing the migratory and invasive capacity of breast cancer cells in culture 85 and by inhibiting EMT through a glycogen synthase kinase-3β (GSK-3β )-dependent mechanism in vivo 86 . Clinical evidence similarly suggests an improvement in the 5-year-survival rate of metastatic patients with NSCLC treated with melatonin in combination with cisplatin and etoposide 87 . Yet, conflicting clinical evidence exists regarding the use and efficacy of melatonin and its potential benefits towards quality of life 88 , and therefore further investigations are required to fully understand the potential beneficial effects of melatonin.
Finally, circadian analyses of the tumor macroenvironment could have unique clinical value. Indeed, considering the complexity of the tumor-host relationship and the potential for this communication to be constantly changing, the tumor-dependent secretome has value as a noninvasive prognostic tool. In this respect it is noteworthy that an increase in plasma branched-chain amino acids (BCAA) is associated with an increased risk for diagnosis of pancreatic cancer 89 . Also, the use of blood-borne tumor-secreted metabolites has been documented with colorectal cancer 90 . Similar strategies have been used in patients with advanced breast cancer 91 or in those diagnosed with pancreatic cancer 92 . Interestingly, profiling the metabolome can also be utilized to gauge treatment efficacy. Indeed, serum metabolome analysis of patients with breast cancer treated with neoadjuvant chemotherapy identified metabolites responsive to treatment, including threonine, isoleucine, glutamine, and linoleic acid 93 . Thus far, these studies have not been conducted over the day-night cycle to determine whether availability of these metabolites is found to be rhythmic. While these studies could have clinical value, we would argue that the time of day could be an important factor to consider given that metabolites such as amino acids and lipids display circadian profiles 94, 95 .
Concluding remarks
The complex network of communication between the circadian clock and tumorigenesis is only beginning to be unraveled (Fig. 3) . At the foundation is strong epidemiological evidence that implicates circadian disruption with cancer. Several lines of genetic evidence from laboratory studies connect disruption of the circadian molecular machinery with lymphoma, HCC, lung cancer, and other tumor types. Intriguingly, preliminary evidence supports a circadian connection with cancer metabolism in an oncogene-driven cell-autonomous manner, such as with MYC. Given that cancer
Box 2 | Cancer-initiating cells and the circadian clock
Studies using GEMMs have revealed that the circadian clock is implicated in determining unique properties of tissue-specific stem cell populations [127] [128] [129] . As these stem cells are thought to share important features with cancer-initiating cells, some questions are raised: does a stem cell clock differ from other clocks and do cancer-initiating cells have a distinct circadian transcriptional program? By extension, it could be speculated that common changes in clock function could be causal to determine both 'stemness' and cancer phenotypes. A number of studies support the notion that elements of the circadian clock regulate stem cell functions. For example, rhythmic oscillations of key secreted factors in the skin, such as bone morphogenetic protein (BMP), regulate stem cells involved in hair regeneration 130 , and BMAL1 transcriptionally controls stem cell regulatory genes to specify epidermal stem cell heterogeneity 127 . Also, a critical chemokine for hematopoietic stem cell (HSC) migration, CXCL12, displays clock-controlled expression 131 . Recent evidence in aged epidermal and muscle stem cells versus hepatocytes demonstrates very different tissue-specific transcriptional control pathways that are unique to stem cell populations 128, 129 . Yet, can the circadian clock alter tumor initiation potential through cancer-initiating cells? Mice carrying an epidermal deletion of Bmal1 crossed with oncogenic Sos1 (also known as Sos; activates the Ras pathway) displayed fewer squamous tumors in the tail versus control keratin-5-expressing Sos mice, which displayed 100% penetrance of neoplastic lesions 127 . However, using a similar keratinocyte-specific mouse model, it was also found that Bmal1 ablation increased cell proliferation and elevated susceptibility to ultraviolet-induced DNA damage 132 . Therefore, how Bmal1 is involved in tumorigenesis through cancer-initiating cells remains unresolved. Moreover, disruption of the canonical circadian molecular machinery depletes leukemic stem cells, and Clock and Bmal1 were reported to be required for growth of acute myeloid leukemia (AML) 82 . These studies suggest that clock function could act in a dual manner in regulating tumorigenesis at the levels of initiation and disease progression. In light of these differing reports, the role of the circadian clock in cancer-initiating cells requires further investigation.
This concept of a dual-functioning circadian clock can be further extended, and interestingly, there are conflicting reports of clock disruption in specific cancer types. For instance, hypermethylation at the CLOCK promoter was found to reduce risk of breast cancer, and a reduced level of Clock expression was found in healthy controls relative to breast cancer tumors 133 . Yet, breast cancer tissue was also found to exhibit hypermethylation of the CRY2 promoter relative to normal controls in estrogen receptor and progesterone (ER/PR)-negative breast cancers, but not in ER/PR-positive tumors 134 . These studies point to possible differences in circadian function and transcriptional output based on cell of origin, prompting further investigation into how the circadian machinery in stem cells is different from that in differentiated cell types. Also, further dissection of the changes in circadian gene expression programs within cancer cell subtypes is needed in addition to analysis of how the clock machinery is altered over the course of transformation from adenomas to adenocarcinomas.
cells utilize nutrients at a high metabolic rate, it is possible that several pathways may be controlled by the circadian clock. However, it remains to be determined how the clock may impinge on such pathways, including amino acid metabolism and availability, the pentose phosphate pathway, and other intracellular energy-generating mechanisms that can potentially be hijacked by cancer cells. Several metabolic pathways are dynamically circadian, and hence the time at which therapeutic targeting of these pathways occurs may be critical. Furthermore, several lines of evidence discussed here point to systemic nutrient repurposing as a means of circumventing typical energy requirements in order to sustain heightened cell proliferation in cancer. These ideas focusing on the circadian clock should be considered when developing pharmacological approaches to target tumor metabolism to dictate survival and proliferation.
